CD8A and myeloid sarcoma: The finding that the frequency of CD20-expressing myelin-specific CD8+ T cells is increased in MS patients compared to control individuals is consistent with an increased activation state and suggested that these cells could be targeted by anti-CD20 mAb therapy.